Improve solubility within the gastrointestinal tract
Adare provides technologies to enable and improve the solubility of drugs with low solubility or an extreme pH-dependent solubility profile. The resulting formulations can offer effective oral dosing of poorly soluble drug candidates, equivalent therapy at lower doses, faster onset of action, and minimization of food effect. The solubility enhancement technologies provided by Adare include Diffucaps® solid solution or solid dispersion.
How It Works
A solid-solution/solid dispersion drug form is contained in layers of excipients and release-controlling polymers. This is combined with a crystallization inhibitor, enhancing bioavailability by maintaining the drug in its amorphous state. The solubility-enhanced beads can be coated with one or more functional polymers to achieve extended-release profiles suitable for once- or twice-daily dosing.
Our innovative solubility enhancement technologies provide:
- Substantial global experience in all aspects
- Effective oral dosing of poorly soluble drug candidates
- Equivalent therapy at lower doses
- Faster onset of action
- Minimization of food effect
- Adjustable dosage strength and dissolution profile to achieve the desired in vivo pharmacokinetic profile
- Enhanced drug solubility in sections of the gastrointestinal tract through combined use with other Adare technologies
Solubility Enhancement Technologies
- Bench-to-pilot scale Spray-drying
- Hot Melt (Leistritz ZSE 18)
- Dyno-mill
- Diffucaps
- Conventional approaches using:
- Cyclodextrins
- Solubilizers
- Surfactants
- Super-disintegrants
Speak With An Expert
Nathan Dormer
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS and Philadelphia, PA facilities, where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.